Table 1.
Cpd | X | Y | Z | W | R1 | R2 | IC50 (μM)a | CC50 (μM)b | SIc |
---|---|---|---|---|---|---|---|---|---|
1 | H | Cl | H | CF3 | Me | i-PrNH- | 0.77 | >25 | 33 |
6a | H | H | H | i-Pr | Me | i-PrNH- | >25 | – | – |
6b | H | Me | H | Me | Me | i-PrNH- | >25 | – | – |
6c | H | Cl | H | CF3 | Ph | i-PrNH- | >25 | – | – |
6d | H | Cl | H | CF3 | Me | 2,4-F2-PhNH- | 0.15 | 7.3 | 78 |
6e | H | Cl | H | F | Me | 2,4-F2-PhNH- | 0.98 | >25 | 26 |
6f | H | Cl | H | NO2 | Me | 2,4-F2-PhNH- | 1.16 | >25 | 21 |
6g | H | F | H | F | Me | 2,4-F2-PhNH- | 1.06 | >25 | 25 |
6h | Cl | Cl | H | Cl | Me | 2,4-F2-PhNH- | 0.29 | >25 | 91 |
6i | H | F | H | F | Me | 1-Piperidinyl | >25 | >25 | 1 |
6j | H | F | H | F | Me | 4-Morpholinyl | >25 | >25 | 1 |
6k | H | F | H | F | Me | n-ButylNH- | >25 | >25 | 1 |
6l | H | F | H | F | Me | 3,4-Cl2-PhCH2O- | 7.8 | >25 | 3 |
6m | H | F | H | F | Me | 2,4-F2-PhCH2NH- | 5.9 | >25 | 3 |
6n | H | F | H | F | Me | 4-F-PhCH2NH- | 17.6 | >25 | 1 |
6o | H | F | H | F | Me | 4-MeO-PhCH2NH- | >25 | >25 | 1 |
6p | H | F | H | F | Me | 3-MeO-PhNH- | >25 | >25 | 1 |
6q | H | F | H | F | Me | 4-MeO-PhNH- | >25 | >25 | 1 |
6r | H | F | H | F | Me | 4-Br-PhNH- | 1.13 | >25 | 28 |
6s | H | F | H | F | Me | 4-Cl-PhNH- | 1.44 | >25 | 22 |
6t | H | F | H | F | Me | 2,3,4-F3-PhNH- | 0.53 | >25 | 48 |
6u | H | F | H | F | i-Pr | 2,3,4-F3-PhNH- | 0.086 ± 0.041d | >25 | 500 |
6v | H | F | H | F | i-Pr | 2,4-F2-PhNH- | 0.79 | >25 | 45 |
6w | Cl | Cl | H | Cl | i-Pr | 2,3,4-F3-PhNH- | 0.100 ± 0.023d | 6.4 | 77 |
6x | Cl | H | H | Cl | i-Pr | 2,3,4-F3-PhNH- | 0.166 ± 0.067d | 10.89 ± 4.29d | 9 |
6y | Cl | Cl | F | Cl | i-Pr | 2,4-F2-PhNH- | 0.129 ± 0.026d | >25 | 231 |
6z | H | Cl | H | CF3 | i-Pr | 2,4-F2-PhNH | 0.13 | 7.3 | 144 |
IC50 and CC50 were derived from the results of at least two independent experiment in VERO.
SI (selectivity index) = CC50/IC50 for inhibiting MERS-CoV infection.
Mean ± SD of four independent tests.